Recommendations for biomarker identification and qualification in clinical proteomics

H Mischak; G Allmaier; R Apweiler; T Attwood; M Baumann; A Benigni; SE Bennett; R Bischoff; E Bongcam-Rudloff; G Capasso; JJ Coon; P D'Haese; AF Dominiczak; M Dakna; H Dihazi; JH Ehrich; P Fernandez-Llama; D Fliser; J Frokiaer; J Garin; M Girolami; WS Hancock; M Haubitz; D Hochstrasser; RR Holman; JPA Ioannidis; J Jankowski; BA Julian; JB Klein; W Kolch; T Luider; Z Massy; WB Mattes; F Molina; B Monsarrat; J Novak; K Peter; P Rossing; M Sánchez-Carbayo; JP Schanstra; OJ Semmes; G Spasovski; D Theodorescu; V Thongboonkerd; R Vanholder; TD Veenstra; E Weissinger; T Yamamoto; A Vlahou

Journal article

Recommendations for biomarker identification and qualification in clinical proteomics

H Mischak, G Allmaier, R Apweiler, T Attwood, M Baumann, A Benigni, SE Bennett, R Bischoff, E Bongcam-Rudloff, G Capasso, JJ Coon, P D'Haese, AF Dominiczak, M Dakna, H Dihazi, JH Ehrich, P Fernandez-Llama, D Fliser, J Frokiaer, J Garin Show all

Science Translational Medicine | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2010

DOI: 10.1126/scitranslmed.3001249

Abstract

Clinical proteomics has yielded some early positive results - the identification of potential disease biomarkers - indicating the promise for this analytical approach to improve the current state of the art in clinical practice. However, the inability to verify some candidate molecules in subsequent studies has led to skepticism among many clinicians and regulatory bodies, and it has become evident that commonly encountered shortcomings in fundamental aspects of experimental design mainly during biomarker discovery must be addressed in order to provide robust data. In this Perspective, we assert that successful studies generally use suitable statistical approaches for biomarker definition an..

View full abstract

University of Melbourne Researchers

Karlheinz Peter Author

Grants

Awarded by European Commission

Funding Acknowledgements

This initiative was supported in part by the Eu-roKUP COST-Action (BM0702; www.eurokup.org), by the European Community's 6th Framework Programme, grant agreement LSHM-CT-2006-037093 (InGenious Hyper-Care), and by the European Community's 7th Framework Programme, grant agreement HEALTH-F2-2009-241544 (SysKID). A.F.D. wishes to acknowledge support of the British Heart Foundation Chair and Programme Grants (BHF RG/07/005/23633). B.A.J. and J.N. acknowledge their support in part from NIH grants DK075868, DK078244, DK082753, DK083663, and DK080301. B.M. and J.P.S. acknowledge the support from the Agence Nationale pour la Recherche (ANR-07-PHYSIO-004-01), the Fondation pour la Recherche Medicale "Grands Equipements pour la Recherche Biomedicale," and the CPER2007-2013 program. J.J. was supported by a grant from Federal Ministry of Education and Research (01GR0807). W.H. acknowledges support by NCI grant CA 128427 and Korean WCU grant R31-2008-000-10086-0. A.V. and J.G. acknowledge support from FP7 DECanBio (grant agreement 201333). O.J.S. acknowledges support from NIH/NCI CA CA085067.